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InﬂuenzaLow pH treatment of inﬂuenza virus hemagglutinin (HA) exposes its relatively conserved stalk domain,
suggesting a potential immunogen with capability to induce broader immune responses. Here, we describe
characterization, immunogenicity, antigenicity, and protective immunity induced by low pH treated
inactivated whole viral vaccine in comparison with the untreated vaccine. The acidic pH treated viral vaccine
showed high susceptibility to proteolytic cleavage and low hemagglutination activity indicating conforma-
tional changes. Immunization of mice with low pH treated viral vaccine induced lower levels of homologous
or heterologous virus-speciﬁc binding and neutralizing antibodies compared to the untreated vaccine. Also,
low pH treated inﬂuenza viral antigen showed lower antigenicity compared to the untreated inﬂuenza viral
antigen. Lower efﬁcacy of cross-protection against heterosubtypic virus was observed in the low-pH treated
vaccine group. The results provide evidence that there is a correlation between protective efﬁcacy and the
stability of vaccines.oad, Atlanta, GA 30322, USA.
lanta, GA 30322, USA. Fax: +1
er), skang2@emory.edu
sease Control and Prevention,
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza virus hemagglutinin (HA) is the major target for inducing
virus-neutralizing antibodies after vaccination. Cleavage of the HA
precursor molecule HAo is a required step to activate virus infectivity
(Klenk et al., 1975; Lazarowitz and Choppin, 1975). The distribution of
activating proteases in the host is one of the determinants of tropism
and pathogenicity (Steinhauer, 1999). HA is a homotrimeric molecule,
each monomer consisting of two disulﬁde-linked glycoproteins, a
globular head of HA1 and a stem domain composed of part of HA1 and
all ofHA2 (Wilson et al., 1981). The globular head contains the receptor-
binding pocket surrounded by variable antigenic sites that have been
identiﬁed by amino acid sequence changes in escape mutants selected
by monoclonal antibodies and in natural variants (Laver et al., 1980;
Laver et al., 1979). The locationsof fourantigenic sites, designatedA,B, C,
and D, agree well with antigenic mapping studies of the HA molecule
using monoclonal antibodies (Gerhard et al., 1981; Wiley and Skehel,
1987). The recurrenceof inﬂuenza virus infection inhumans is primarily
due to mutations occurring in the antigenic sites of the HA1 globular
head domains.Inﬂuenza viruses are known to fuse with liposomes at the acidic pH
found in lysosomes but not at neutral pH (Maeda et al., 1981;Yoshimura
et al., 1982). Structural analysis of the HA molecule shows that the
hydrophobic fusion peptide is located in the stem region of theHA spike
proximal to the viral envelope (Wiley et al., 1981; Wilson et al., 1981).
The stem is mainly composed of two antiparallel α-helices of unequal
length linked by anextendedpolypeptide chain. At the pHofmembrane
fusion, HA increases its hydrophobic properties due to exposure of the
fusion peptide, and undergoes additional conformational changes that
allow for proteolytic cleavage at newly-susceptible residues in the HA1
subunit (Skehel et al., 1982). This acid-induced change of HA is largely
irreversible, even when the molecule is returned to neutral pH, and
includes the loss of the trimeric structure of the globular head domains
(Bizebard et al., 1995; Ruigrok et al., 1988; Skehel et al., 1982).
Meanwhile, the stem structure is known to remain in a trimeric
structure despite its extensive refolding and reorganization (Bullough
et al., 1994; Ruigrok et al., 1988).
Previous studies demonstrated that certain monoclonal antibodies
were reactive to the low-pH induced but not to the native
conformation of HA, especially on the stem region of the HAmolecule,
where HA2 is relatively well conserved among inﬂuenza A viruses
(Ekiert et al., 2009; Kostolansky et al., 1988; Vanlandschoot et al.,
1998; Webster et al., 1983). Some of these monoclonal antibodies
have been reported to show broadly neutralizing activity, probably by
preventing the fusion step of virus entry (Prabhu et al., 2009; Sui et al.,
2009; Wang et al., 2010b). Also, vaccines designed to induce
antibodies against the stalk of HA were recently shown to provide
cross protection against lethal challenge (Bommakanti et al., 2010;
197F.-S. Quan et al. / Virology 417 (2011) 196–202Hashem et al., 2010; Stanekova et al., 2011; Steel et al., 2010; Wang
et al., 2010a). However, the efﬁcacy of cross protection was relatively
low, not being able to prevent weight loss.
In the present study, we have addressed the question whether the
low-pH induced structural and conformational changes in the context
of whole inﬂuenza virus might provide an immunogen that can
induce broad cross protection. We compared immunogenicity,
antigenicity, and cross protection of the inactivated H1 inﬂuenza
virus as a vaccine before and after treatment at pH 5.0.
Results
Exposure of inactivated virus to acidic pH lowers hemagglutination activity
In order to expose conserved domains of HA2, inactivated inﬂuenza
virus (A/PR8) was exposed to the acidic pH of 5.0. It is known that low
pH induced conformational changes in HA result in susceptibility to
proteolytic cleavage (Skehel et al., 1982). Untreated inﬂuenza virus did
not show differences in the pattern of viral proteins separated on the
SDS-PAGE before and after proteolytic digestion with a low concentra-
tion of trypsin as shown by Coomassie blue staining (Fig. 1A) and
western blot (Fig. 1B). In contrast, treatment of low pH treated
inactivated A/PR8 viruswith the same concentration of trypsin resulted
in cleavage of the HA proteins as shown by a decrease in the full length
HA1 protein (Figs. 1A and B), and the appearance of lower molecular
weight digestion products (Fig. 1B, column 4). These observations
conﬁrm that exposure of inactivated virus to low pH resulted in the
characteristic HA structural rearrangements, and are consistent with a
previous study on bromelain-released ectodomains of HA (Skehel et al.,
1982). The hemagglutination activity of inactivated virus after exposure
to low pHwas found to be signiﬁcantly reduced by 4 to 5 fold compared
to the untreated inactivated inﬂuenza virus (Fig. 1C). These results
indicate that low pH induced conformational changes in inactivated
vaccines result in structural changes that confer increased susceptibility
to proteolytic cleavage aswell as a decrease in receptor binding activity.
Antibody responses to low pH exposed inﬂuenza vaccines
We hypothesized that changes in the conformation and receptor
binding sites in HA would affect the immunogenicity and protective
efﬁcacy of the inﬂuenza virus vaccine. To test this hypothesis, groups ofBA
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Fig. 1. Low pH treated inactivated virus is susceptible to proteolytic cleavage and shows lowe
of low pH treated and mock treated A/PR8 virus. (A and B) Inactivated A/PR8 virus was expo
was performed at neutral pHwith TPCK-treated trypsin.Western blot was probed withmous
Arrowhead indicates an HA1 cleavage product after trypsin treatment. Untreated: virus at ne
treatment at pH 5.0. Concentrations of trypsin used are indicated 0 and 20 (μg/ml). (C) Hem
untreated or low-pH treated A/PR8 virus (1.29 mg/ml, 50 μl) was used to determine hemagg
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Untreated: A/PR8 virus suspended in neutral pH PBS buffer. Low-pH: low-pH treated A/PR8mice were intranasally immunized with 25 μg of untreated or low-pH
treatedA/PR8vaccines atweeks 0 and4. Serumsampleswere collectedat
3 weeks after boost vaccination and used for determination of antibody
titers. When antibody responses were compared by using untreated
A/PR8 virus as anELISA coating antigen (Fig. 2A), total IgG antibody titers
were higher in the untreated A/PR8 group compared to the group that
was immunized with low pH treated A/PR8 virus vaccine. The untreated
A/PR8 group showed higher levels of antibodies even to the low-pH
treated A/PR8 antigen compared to the low-pH treated A/PR8 group.
Since we observed some differences in total IgG antibody responses,
isotypes of IgG antibodies were determined. High levels of IgG2a and
similar levels of IgG1 and IgG2b isotype antibodies reactive to untreated
A/PR8 virus antigen were observed in the untreated A/PR8 group
(Fig. 2B). In the low pH treated A/PR8 group, both antibody isotypes
reactive to untreated A/PR8 virus antigen were detected at lower levels
compared to the untreated A/PR8 group (Fig. 2B). The untreated A/PR8
group showed higher levels of isotype antibodies even when isotype
antibodies were determined using low-pH treated A/PR8 virus as an
ELISA antigen. Particularly, immunization with low-pH treated A/PR8
antigen was not as effective in inducing IgG isotype antibodies reactive
even to the same low-pH treated vaccine antigen. These results suggest
that the low pH exposed A/PR8 virus is less effective in eliciting
antibodies reactive to itself or A/PR8 antigen.
Low pH treated inﬂuenza vaccines do not induce increased cross-reactive
antibody responses
We determined whether the low-pH treated inactivated virus
might induce enhanced cross reactivity to different viruses. The group
of mice immunized with low-pH exposed A/PR8 vaccines showed
approximately 4 fold lower titers of antibodies reactive to thehomologous
A/PR8 virus compared to the untreated A/PR8 vaccine group (Fig. 3).
When the H3N2 heterosubtypic viral antigen (A/Philippines/82) was
used as an ELISA antigen, 4 fold lower antibody titers were also
observed, and they were proportionally reduced in both untreated and
low-pH treated A/PR8 groups (Fig. 3). The low-pH treated inﬂuenza
A/PR8 virus vaccine induced approximately 4 fold lower antibody titers
cross-reactive to the heterologous H1N1 A/WSN/33 or heterosubtypic
H3N2 A/Philippines/82 virus antigens compared to untreated A/PR8
viral vaccine. Therefore, the antibody reactivity of immune sera from
low-pH treated virus is rather speciﬁc although the levels were low.C -pH 
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Fig. 2. Low pH treated inactivated virus induces lower antibody responses and shows
less reactivity with immune sera. (A) Total IgG antibody responses reactive to untreated
or low-pH treated A/PR8 viral antigens. Untreated A/PR8 sera: immune sera from mice
immunized with untreated inactivated A/PR8 virus kept at neutral pH. Low-pH A/PR8
sera: immune sera from mice immunized with low-pH treated inactivated A/PR8 virus.
X-axis; untreated or untreated Ag: antibody titers reactive to untreated A/PR8 virus
used as an ELISA antigen. Low-pH: antibody titers reactive to low-pH treated A/PR8
virus used as an ELISA antigen. Signiﬁcances were found between low-pH and
untreated groups either using low-pH treated or untreated A/PR8 viral antigen
(Pb0.01). (B) Isotype antibodies reactive to untreated A/PR8 viral antigen. IgG1, IgG2a
and IgG2b antibodies were determined by ELISA using untreated A/PR8 virus as an
antigen. Signiﬁcance was found between IgG2a and IgG1 from the untreated control
(Pb0.001) and between untreated A/PR8 and low-pH treated A/PR8 groups (Pb0.001).
(C) Isotype antibodies reactive to low-pH treated A/PR8 viral antigen. IgG1, IgG2a and
IgG2b antibodies were determined by ELISA using low-pH treated A/PR8 virus as an
antigen. A signiﬁcant difference was found between untreated A/PR8 and low-pH
treated A/PR8 groups (Pb0.001).
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Fig. 3. Antibody responses cross-reactive to heterologous and heterosubtypic inﬂuenza
viruses. IgG antibody responses were determined and compared using homologous (A/
PR8 H1N1), heterologous (A/WSN/33 H1N1), or heterosubtypic (A/Philippines/82
H3N2) virus as an ELISA antigen. Untreated A/PR8 sera: immune sera from mice
immunized with neutral pH inactivated A/PR8 virus kept at neutral pH. Low-pH A/PR8
sera: immune sera from mice immunized with low-pH treated inactivated A/PR8 virus.
Signiﬁcance was found between low-pH and untreated mouse groups (Pb0.001) in
antibody titers reactive to different inﬂuenza viral antigens tested. IgG antibody titers
reactive to the homologous virus were higher than those binding to heterologous
inﬂuenza antigens (Pb0.001).
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not more effective in inducing cross reactive antibody responses
compared to the untreated viral vaccine.
Low-pH treated inﬂuenza vaccines are less effective in inducing cross-
reactive neutralizing antibody responses
The A/PR8 virus vaccine was effective in inducing high titers of
neutralizing antibody responses against the homologous A/PR8 virus,which were 6 fold higher than responses induced by the low-pH
treated vaccine (Fig. 4). Signiﬁcant levels of cross-neutralizing
antibodies against the closely related A/WSN/33 virus were observed
in the sera of the untreated A/PR8 immunized group although these
titers were approximately 9 fold lower than those against the
homologous virus. The low-pH treated group also showed signiﬁcant
cross neutralizing antibody titers only 2 fold lower than the untreated
group. Cross-neutralizing antibodies against the antigenically unre-
lated heterosubtypic H3N2 A/Philippines/82 were observed with 80
fold lower levels in the sera of the untreated A/PR8 vaccine
immunized group compared to those against the homologous virus.
The low-pH treated A/PR8 vaccine group did not increase levels of
antibodies neutralizing heterosubtypic A/Philippines/82 virus com-
pared to the untreated group (Fig. 4). Therefore, these results suggest
that low-pH induced conformational changes in HA do not increase
cross-neutralizing antibody responses compared to the untreated
inﬂuenza vaccine.
Low-pH treated inﬂuenza vaccine confers reduced cross protection
To determine heterosubtypic protection against challenge with
H3N2 A/Philippines/82 virus, groups of mice were challenged with a 2
LD50 dose of A/Philippines/82 virus, and their body weight changes
and survival rates were monitored for 16 days. Unimmunized naïve
mice displayed a rapid weight loss until day 8 post infection and the
surviving mice showed a slow recovery (Fig. 5). Mice that were
immunized with the untreated A/PR8 virus did not show any changes
in body weights and all survived the challenge. In contrast, a
substantial loss in body weight was observed in mice immunized
with the low-pH treated virus (Fig. 5A). Despite the loss in body
weight, the low-pH treated vaccine provided 100% survival against
the heterosubtypic virus challenge compared to the 30% survival in
naïve mice (Fig. 5B). Consistent with the results of antibody
responses, the heterosubtypic challenge experiment suggests that
the low-pH treated vaccine is less effective in inducing cross-
protective immunity than the untreated inﬂuenza vaccine.
It is also important to determine the protective efﬁcacy against
inﬂuenza A/WSN/33 virus since cross-reactive antibodies induced by
low-pH treated vaccines were lower for this virus (Figs. 3 and 4). As
shown in Fig. 6, we determined the capability of immune sera to
provide protection against A/WSN/33 virus in naïve mice as described
previously (Song et al., 2011). All mice that received naïve sera
showed severe body weight loss and were not protected (Fig. 6).
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complete protection against A/WSN virus at a dilution of 3 fold
(Figs. 6A and B). With 6 fold-diluted immune sera, mice that received
immune sera from the low-pH treated vaccine group displayed a
transient loss of body weight which was not seen with serum from
mice immunized with untreated vaccine (Figs. 6C and D). These
results provide further evidence that low-pH treated vaccine does not
induce more effective cross protective immunity compared to the
untreated vaccine.
Discussion
Exposing the untreated virus to an acid environment was shown to
induce a signiﬁcant conformational change in HA such that the HA2
domain is relocated to a favorable position to trigger membrane
fusion of the virus and the target cell (Maeda et al., 1981; Ruigrok
et al., 1988; Skehel et al., 1982; White et al., 1982). In the present
study, we observed two obvious changes after exposing inactivated
inﬂuenza virus to pH 5.0. The HA protein in the low-pH treatedinactivated virus became highly susceptible to proteolytic cleavage by
trypsin, which is consistent with previous observations of increased
HA hydrophobic properties and proteolytic cleavage after acidiﬁcation
(Skehel et al., 1982). Fig. 7 shows a structural depiction of the HA
conformational changes that are induced upon exposure to low pH. In
this model, hydrophobic fusion domains are likely to be exposed. Also,
an approximately 4 fold decrease in hemagglutination activity was
observed in the low-pH treated inactivated virus compared to the
untreated virus vaccine, indicating potential changes in the receptor
binding globular regions. It is possible that low-pH induced
conformational changes might have occurred in the HA2 hydrophobic
stalk region domains proximal to the viral membrane as well as in the
globular head regions of receptor binding sites. These changes are
consistent with an electron microscopic observation that stalks in the
HA2 domain change to thinner and longer spikes on virus particles in
the fusion pH conformation (Wharton et al., 1995).
We found that immunization with low-pH treated inﬂuenza
vaccines induced 3 to 4 fold lower levels of antibodies reactive to
either untreated or low-pH treated inﬂuenza antigens compared to
standard untreated inﬂuenza vaccines. These results have important
implications. Protective immune responses by current inﬂuenza
vaccination are largely targeted to the major antigenic regions in
the HA1 globular head domain where receptor binding pockets are
located. Low pH treatment causes changes in the receptor binding
sites and in the globular head domain, which might alter the effective
antigenic and immunogenic target sites. These changes in tertiary
structures lead to speciﬁc changes in the antigenic sites B and D as
shown by reactivity of monoclonal antibodies (Daniels et al., 1983;
Yewdell et al., 1983). A study using monoclonal antibodies revealed
that two antigenic regions that are located at the tip and interface of
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1983). It is also speculated that maintenance of HA receptor binding
activity might be needed for effective interaction with antigen
presenting cells. In previous studies, the stability of inﬂuenza vaccines
as measured by levels of hemagglutination activity was shown to
correlate with ability to induce protective immune responses (Kim
et al., 2010; Quan et al., 2010; Quan et al., 2009). Another possibility is
that the head domains of these immunogens might have short half-
lives probably due to proteolytic degradation. Thus, these results
suggest that low immunogenicity and antigenicity of acidic pH treated
virus might be related to changes in globular head regions.
Regions of HA that are cross-reactive antibody targets have not been
well deﬁned yet. Cross reactive antibody responses elicited by
immunization with low-pH treated inﬂuenza vaccines were several
fold lower compared to the untreated vaccine. Similarly, low-pH treated
inﬂuenza vaccines were not as effective in inducing neutralizing
antibody responses against homologous or closely related strains.
Both the untreated and low-pH treated vaccines showed low levels of
heterosubtypic cross neutralizing antibody titers. In contrast, there was
over 4 fold difference in levels of cross reactive binding antibodies
between the untreated and low-pH treated vaccines. Therefore, it is
speculated that the globular head domain of HA could be a target for
inducingmore cross-reactive antibodies than the exposed stalk domain
in the low-pH treated vaccine. Consistent with our observations,
previous studies demonstrated that monoclonal antibodies speciﬁc for
the low pH treated inﬂuenza viruses were not capable of blocking viral
growth whereas those speciﬁc for the untreated virus neutralized virus
to high titers (Webster et al., 1983).
It is interesting to note that the low-pH vaccine conferred 100%
protection against the A/Philippines H3N2 virus. Low levels of cross-
reactive antibody responses might play a role in conferring protection
against lethal infection with a low dose of heterosubtypic virus. There
is also a possibility that cellular and/or humoral immunity to internal
proteins might have contributed to protection against the hetero-
subtypic virus. In previous studies, approaches presenting headless
HA containing the conserved stalk domain or HA2-based synthetic
peptide coupled to the carrier protein keyhole limpet hemocyanin
were recently demonstrated to confer potential broad cross-protec-
tion against lethal infection (Steel et al., 2010; Wang et al., 2010a).
Also, recent studies demonstrated that antibodies to the conserved
fusion peptides contribute to weak heterosubtypic cross protection
against lethal infection (Hashem et al., 2010; Prabhu et al., 2009;
Stanekova et al., 2011).
The current study indicates important implications on immunoge-
nicity and cross protective efﬁcacy of inﬂuenza vaccines containing HA
with conformational alterations by a low pH environment. Also, the
present study provides relevant information regarding vaccine stability,
formulation, and protective efﬁcacy. Storage and/or vaccine inactivation
conditions that might alter HA functional activity might be parameters
affecting the efﬁcacy of vaccines. Nevertheless, future studies may
enable development of inﬂuenza vaccines without alterations in the
receptor binding sites but with conserved epitopes exposed.
Materials and methods
Virus and cells
Inﬂuenza viruses A/PR8/34 (H1N1), A/WSN/33 (H1N1) and A/
Philippines/2/82 (H3N2)were grown in 10-day-old embryonated hen's
eggs and puriﬁed from allantoic ﬂuids by using a discontinuous sucrose
gradient (15%, 30%, and 60%). Inactivation of the puriﬁed virus was
performed bymixing the virus with formalin at a ﬁnal concentration of
1:4000(vol/vol) asdescribedpreviously (Quanet al., 2008). Inactivation
of the virus was conﬁrmed by plaque assay on conﬂuent monolayers of
Madin–Darby canine kidney (MDCK) cells and by inoculation of the
virus into 10-day-old embryonated hen's eggs. For challenge experi-ments, mouse-adapted A/Philippines/2/82 (H3N2) virus was prepared
as lung homogenates from intranasally infected mice and used for
challenge.
Low pH treatment of inactivated virus and trypsin cleavage
Inactivated egg-grown A/PR8/34 virus (A/PR8) in 150 μl of phos-
phate-buffered saline (PBS) at a protein concentration of 3 mg/ml was
mixed with 24.4 μl of low pH buffer (30 mM H3PO4, 150 mM NaCl,
2.7 mM KCl) to reduce pH to 5.0, followed by incubation at 37 °C for
10 min. 174 μl of neutralizing buffer (86 mMNa2HPO4, 2.7 mMKCl, and
150 mM NaCl) were added to the mixture to neutralize the pH. To
examine the low pH conformational change, the PBS buffer treated
(untreated) control and low-pH treated inactivated A/PR8 viruses
(1.29 mg/ml after treatment) were digested in the absence or presence
of 20 μg/ml of TPCK trypsin at 37 °C for 10 min. The trypsin-mediated
cleavage products were conﬁrmed by Coomassie blue staining and
Western blot using mouse anti-A/PR8/34 virus serum.
Hemagglutination activity assay
Low-pH treated and untreated inactivated A/PR8 virus vaccines
were serially diluted and used to determine their hemagglutination
activity titers. Serially diluted A/PR8 virus vaccines (50 μl) were
incubated with 50 μl of 0.5% chicken erythrocytes in each well. The
highest dilution of low-pH treated and untreated inactivated A/PR8
viruses capable of hemagglutination was scored as the HA titer.
Presented data are the means with standard deviation from three
independent replicate experiments.
Immunization and challenge
Female BALB/c mice aged 6 to 8 weeks were purchased from
Charles River Laboratories and used for immunization studies. Mice
were intranasally immunized with 50 μl phosphate-buffered saline
(PBS) containing 25 μg of inactivated A/PR8 virus treated with low-pH
at days 0 and 30. The same amount of inactivated A/PR8 virus was
used as an untreated control for comparison. For challenge infections,
isoﬂurane-anesthetized mice were challenged with A/Philippines/82
(2×LD50) at week 4 after boost. Mice were observed daily to monitor
changes in body weight and to record survival rates (25% loss in body
weight as the Institutional Animal Care and Use Committee (IACUC)
endpoint). All animal experiments and husbandry involved in the
studies presented in this manuscript were conducted under the
guidelines of the Emory University IACUC. Emory IACUC operates
under the federal Animal Welfare Law (administered by the USDA)
and regulations of the Department of Health and Human Services.
Enzyme-linked immunosorbent assay (ELISA)
Blood samples were collected by retro-orbital plexus puncture
before immunization and 3 weeks after boost. Samples were then
spun in amicrocentrifuge for 10 min and supernatants were collected.
Inﬂuenza virus-speciﬁc immunoglobulin IgG, IgG1, IgG2a, and IgG2b
antibodies (isotypes) were determined in sera by enzyme-linked
immunosorbent assay (ELISA). As ELISA coating antigens, puriﬁed
egg-grown inactivated inﬂuenza A/PR8, A/WSN, or A/Philippines/2/82
virus (4 μg/ml) was coated onto 96-well microtiter plates using 100 μl
in coating buffer (0.1 M sodium carbonate, pH 9.5) at 4 °C overnight.
The serum samples were serially diluted and added onto plates after
blocking with 3% bovine serum albumin. The plates were then
incubated with horseradish peroxidase-labeled goat anti-mouse
IgG, IgG1, IgG2a and IgG2b antibodies at 37 °C for 1.5 h. The substrate
O-phenylenediamine in citrate–phosphate buffer (pH 5.0) containing
0.03% H2O2 was used to develop color. The optical density at 450 nm
was read using an ELISA reader.
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Mouse sera were inactivated at 56 °C for 30 min and then serially
diluted in DMEM using 96-well assay plates and virus neutralizing
activities were determined as described (Quan et al., 2007). Live
inﬂuenza virus (A/PR8, A/WSN, or A/Philippines/2/82) was diluted in
DMEMmedia and incubatedwith serially dilutedmouse sera at 37 °C for
1 h and then added to prewashed, conﬂuentmonolayers of MDCK cells.
Plates were incubated for 2 days, the cells were ﬁxed with 0.25%
glutaraldehyde and stained with 1% crystal violet to visualize plaques.
The mean percent plaque reduction by sera from vaccinated mice
compared to sera fromnaïve andmediumcontrolwere determined. The
highest serum dilution showing 50% plaque reduction in comparison to
the negative control was taken as the neutralizing-antibody titer.
Statistics
All parameters were recorded for individuals within all groups.
Statistical comparisons of data were carried out using the analysis of
variance and Npar one-way Kruskal–Wallis tests of the PC-SAS system.
P values of b0.05 were considered signiﬁcant.
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